Itraconazole to Prevent Recurrent Barrett's Esophagus
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Recurrent Barrett's esophagus (BE) that occurs at the rate of 12.4%/year is the Achilles heel
of the endoscopic treatment of high-risk BE. Over time, after eradication, BE ultimately
recurs in as many as 30-50% of the patients putting them at risk for esophageal
adenocarcinoma (EAC), thereby undoing the benefits of an effective initial therapy. Also,
recurrences need retreatments that increase costs and complications including strictures and
refractory ulcerations. A therapy to prevent recurrent BE does not currently exist.
Itraconazole with its ability to inhibit important molecular pathways related to BE
development could enhance the long-term effectiveness of endoscopic eradication of high-risk
BE, thereby promoting a long-term cure
Phase:
Phase 1
Details
Lead Sponsor:
University of Kansas Medical Center
Collaborator:
University of Texas, Southwestern Medical Center at Dallas